Literature DB >> 11550283

Identification of four new translocations involving FGFR1 in myeloid disorders.

J Sohal1, A Chase, S Mould, M Corcoran, D Oscier, S Iqbal, S Parker, J Welborn, R I Harris, G Martinelli, V Montefusco, P Sinclair, B S Wilkins, H van den Berg, D Vanstraelen, J M Goldman, N C Cross.   

Abstract

The 8p11 myeloproliferative syndrome (EMS) is associated with three translocations, t(8;13)(p11;q12), t(8;9)(p11;q33), and t(6;8)(q27;p11), that fuse unrelated genes (ZNF198, CEP110, and FOP, respectively) to the entire tyrosine kinase domain of FGFR1. In all cases thus far examined (n = 10), the t(8;13) results in an identical mRNA fusion between ZNF198 exon 17 and FGFR1 exon 9. To determine if consistent fusions are also seen in the variant translocations, we performed RT-PCR on four cases and sequenced the products. For two patients with a t(8;9), we found that CEP110 exon 15 was fused to FGFR1 exon 9. For two patients with a t(6;8), we found that FOP exon 5 (n = 1) or exon 7 (n = 1) was fused to FGFR1 exon 9. To determine if FGFR1 might be involved in other myeloid disorders with translocations of 8p, we developed a two-color FISH assay using two differentially labeled PAC clones that flank FGFR1. Disruption of this gene was indicated in a patient with a t(8;17)(p11;q25) and Ph-negative chronic myeloid leukemia in association with systemic malignant mast cell disease, a patient with acute myeloid leukemia with a t(8;11)(p11;p15), and two cases with T-cell lymphoma, myeloproliferative disorder, and marrow eosinophilia with a t(8;12)(p11;q15) and ins(12;8)(p11;p11p21), respectively. For the patient with the t(8;11), the chromosome 11 breakpoint was determined to be in the vicinity of NUP98. We conclude that 1) all mRNA fusions in EMS result in splicing to FGFR1 exon 9 but breakpoints in FOP are variable, 2) two-color FISH can identify patients with EMS, and 3) the t(8;17)(p11;q25), t(8;11)(p11;p15), t(8;12)(p11;q15), and ins(12;8)(p11;p11p21) are novel karyotypic changes that most likely involve FGFR1. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550283     DOI: 10.1002/gcc.1177

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

2.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

3.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 4.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

5.  Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

Authors:  Monica Kasbekar; Valentina Nardi; Paola Dal Cin; Andrew M Brunner; Meghan Burke; Yi-Bin Chen; Christine Connolly; Amir T Fathi; Julia Foster; Molly Macrae; Steven L McAfee; Kristin McGregor; Rupa Narayan; Aura Y Ramos; Tina T Som; Meghan Vartanian; Robb S Friedman; Karim A Benhadji; Gabriela S Hobbs
Journal:  Blood Adv       Date:  2020-07-14

Review 6.  Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Authors:  Kai Hung Tiong; Li Yen Mah; Chee-Onn Leong
Journal:  Apoptosis       Date:  2013-12       Impact factor: 4.677

Review 7.  [Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review].

Authors:  Y T Liu; J W Zhao; J Feng; Q H Li; Y M Chen; L G Qiu; Z J Xiao; Y Li; B F Gong; X Y Gong; Y C Mi; J X Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-10-14

Review 8.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

9.  Restored expression of vitamin D receptor and sensitivity to 1,25-dihydroxyvitamin D3 in response to disrupted fusion FOP2-FGFR1 gene in acute myeloid leukemia cells.

Authors:  Aleksandra Marchwicka; Aoife Corcoran; Klaudia Berkowska; Ewa Marcinkowska
Journal:  Cell Biosci       Date:  2016-02-02       Impact factor: 7.133

10.  FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Authors:  Elie Traer; Jacqueline Martinez; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Tibor Kovacsovics; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.